Showing posts sorted by relevance for query Brenda Baletti. Sort by date Show all posts
Showing posts sorted by relevance for query Brenda Baletti. Sort by date Show all posts

Friday, May 15, 2026

Fluoride Study Claiming No Effect on IQ Has ‘Basically No Connection to Reality,’ Critics Say


Fluoride Study Claiming No Effect on IQ Has ‘Basically No Connection to Reality,’ Critics Say

By Brenda Baletti, Ph.D.

Post on May 15, 2025



Source

Mainstream media are widely promoting a study claiming that community water fluoridation has no effect on IQ, but critics told The Defender the study contains fundamental methodological errors that invalidate the authors’ conclusions. The Defender asked to be included in a media call with the study’s author, but was denied access.

Experts who analyzed a recent study claiming that fluoride exposure from drinking water doesn’t affect IQ told The Defender the study was deceptive and relied on a flawed methodology.

The “highly anticipated long-term study,” published April 13 in Proceedings of the National Academy of Sciences (PNAS), was widely cited by media and proponents of water fluoridation as evidence that there is no difference in IQ between people who drank water containing fluoride at the level currently recommended by U.S. public health agencies and people who didn’t.

But Chris Neurath — a research director for the American Environmental Health Studies Project who analyzed the study — identified flaws in the data used for the study and the authors’ conclusions.

Neurath said that one of the “most deceptive parts” of both the media coverage and the study itself was the claim that it studied community water fluoridation, and that it was a comparison between two groups — people exposed to fluoridation and people who weren’t.

Neurath found that the authors didn’t actually measure how much fluoride study participants consumed.

They also didn’t study people who were exposed to fluoride as neonates or young children — the very groups that research shows are most affected by fluoride exposure.

For example, the researchers used data from the Wisconsin Longitudinal Study, which tracked about 10,000 people in the 1957 Wisconsin high school graduating class. Participants took IQ tests in high school and cognitive tests later in life — at ages 53, 64, 72 and 80.

That means the study participants were born in about 1939 — six years before community water fluoridation began anywhere in the U.S.

Given that community water fluoridation didn’t even exist when the study participants were born, no one in the study was exposed to it during the critical developmental years when it can affect IQ — and few people were exposed to fluoridated water at all.

Attorney Michael Connett, who represents plaintiffs in the landmark lawsuit against the U.S. Environmental Protection Agency that put concerns about water fluoridation on the national radar, criticized the study in a post on X.

He wrote:

“The study’s use of a clearly erroneous measurement of early life exposure to fluoridated water made it virtually impossible for this study to detect an association between early-life fluoride exposure and IQ.

“It’s like trying to determine if prenatal exposure to Tylenol is associated with autism by determining the Tylenol use of the child’s neighbor rather than the child’s mother.”

‘Very faulty’ exposure method ‘invalidates the entire study’

Neurath and Connett also criticized the PNAS study’s choice of wells to estimate fluoride exposure.

The researchers assumed that if a Wisconsin county had a single well found to have naturally elevated levels of fluoride at the currently recommended 0.7 milligrams per liter (mg/L), then everyone in the county was exposed to that level of fluoride.

Connett said that assumption, at the heart of the study, “has basically no connection to reality” because fluoride levels in a single well can’t provide information about fluoride in other wells, “let alone ‘all’ wells.”

The researchers identified the wells using U.S. Geological Survey data collected between 1988 and 2017, which contained information on about two wells per county in Wisconsin.

Neurath compared the data used by the study authors to data on more detailed studies on well fluoridation from the state of Wisconsin — data that the authors of the PNAS study didn’t use.

He found that most of the counties included in the new study had only one well containing fluoride at 0.7 mg/L, and that some had up to 30 wells with levels measuring well below that threshold.

In one example from Sheboygan County, Neurath found that the single well identified as containing fluoride wasn’t even a drinking water well — it was a “monitoring well” next to an agricultural field. All other wells tested in the county had fluoride levels ranging from 0 to 0.2 mg/L.

Neurath said that most Wisconsin residents weren’t even getting water from private wells — they relied on public water systems. At the time, about 3% of public water systems had naturally high levels of fluoride.

He concluded that the study used “a very faulty exposure measure,” which he said, “invalidates the entire study.”

Lead author denies Defender access to reporter call, deflects scrutiny

Researchers from the University of Minnesota, the University of Wisconsin and the University of Michigan conducted the PNAS study.

Lead author Rob Warren, Ph.D., was scheduled to speak with reporters on Tuesday in 15-minute slots to promote the study. The Defender signed up but was denied access. At least one local news station interviewed Warren that day.

Warren, a sociologist, told reporter Connor Rhiel that concerns about fluoride and IQ typically draw on research from small communities in Iran and China with abnormally high fluoride levels for “weird geological reasons” — and weren’t relevant to U.S. policy.

He said his team chose their approach because large cohort studies tracking fluoride exposure and cognitive outcomes over time are “relatively rare” and difficult to conduct.

He did not mention the major North American cohort studies — published in top journals and most often cited by fluoride critics — already conducted in the U.S., Canada, and Mexico, which identified the link.

Warren said his research shows that children drinking optimally fluoridated water have nothing to fear for their cognition or IQ.

In a similar paper published last year — which critics also flagged for lacking any measure of fluoride exposure during gestation or infancy — he went further, claiming fluoride provided a cognitive benefit, a claim that drew sharp criticism.

When the local reporter asked whether this study found any benefits from fluoride exposure, Warren didn’t mention them. Instead, he offered general remarks that fluoride is good for teeth.

The Defender submitted its intended interview questions to Warren via email Tuesday, asking him to explain and justify the study’s assumptions about fluoride exposure.

Warren had not responded as of press time today.

Brenda Baletti

Saturday, November 9, 2024

Vaccine ‘Quietly’ Pulled Off Market in 2007 Now Linked to 19 Diseases — 35 Million Babies Who Got the Shot Now at Risk as Adults

Vaccine ‘Quietly’ Pulled Off Market in 2007 Now Linked to 19 Diseases — 35 Million Babies Who Got the Shot Now at Risk as Adults

By Brenda Baletti, Ph.D.

Posted on November 9, 2024




The thimerosal-free HibTITER pediatric vaccine marketed by Wyeth from 2003 through 2007 was associated with 19 different medical conditions, according to a study published Tuesday in the International Journal of Risk & Safety in Medicine.

The conditions include life-threatening side effects at rates “significantly higher” than other Hib vaccines.

The study, by Children’s Health Defense (CHD) researcher Karl Jablonowski, Ph.D., and Brian Hooker, Ph.D., CHD chief scientific officer, compared adverse events among children who received HibTITER to those among children who received other Hib vaccines.

Haemophilus influenzae type b (Hib) is a bacterium that can cause illnesses ranging from ear infections to pneumonia to meningitis. Vaccines for Hib in young children were first licensed in 1987. The Centers for Disease Control and Prevention (CDC) recommends Hib vaccines for infants at age 2 months.

Wyeth, now Pfizer, sold HibTITER from the time it was licensed in 1990 until 2007. In 2003, the company reformulated the vaccine to remove thimerosal, a type of mercury, after public outcry over the dangers of mercury in vaccines.

In 2007, Pfizer “quietly” pulled the reformulated HibTITER vaccine off the market, Hooker told The Defender — a move he said was concerning, in light of the vaccine’s “relationship to many adverse events in children.”

To assess those adverse events, Jablonowski and Hooker analyzed data from 277,484 children between 2003-2007 — when the thimerosal-free HibTiTER was available — using the publicly available Florida Medicaid database.

They corroborated their findings by analyzing data for the vaccine from the Vaccine Adverse Event Reporting System (VAERS), a passive public reporting system jointly administered by the CDC and the U.S. Food and Drug Administration (FDA).

The researchers identified medical conditions for infants vaccinated with any Hib vaccine within 30 days of the shot. The Medicaid data revealed 19 different diagnoses associated with HibTITER at frequencies significantly higher than those associated with other Hib vaccines. They also verified 14 of those diagnoses in VAERS.

The adverse events, ranging from mild to life-threatening, included respiratory, gastrointestinal, dermatologic and generalized infections; ear, nose and throat medical contitions; and other conditions.

None of the serious or even life-threatening conditions identified were listed as possible adverse events on the package insert for HibTITER.

The authors’ findings “have profound medical implications for the estimated 35 million Americans between the ages of 16 and 33 who received the vaccine,” they wrote.

Credit: Matt Veligdan

VAERS ‘screaming’ problem with HibTITER for decades

The first Hib conjugate vaccine, which combines a weak antigen with a stronger one to elicit a more robust immune response to the weak antigen, was licensed in 1987 for children 18 months and older, and in 1990 for infants 2 months and older.

Following the approval of the first Hib conjugates, rates of Hib disease in young children dropped dramatically — 92%, from 37 per 100,000 in 1989 to 3 per 100,000 by 2008.

While numerous safety studies found the vaccine to be safe and the side effects to be transient, Jablonowski and Hooker wrote that those studies were “underpowered” — meaning the sample sizes were too small to detect potential safety issues.

The clinical trial used to declare the vaccine’s safety consisted of investigators calling families 72 hours after vaccination to see how the infants were doing. On that basis, they concluded the vaccine was “safe and effective,” the authors wrote.

“Since VAERS first went live in July of 1990 the data started screaming that something was wrong with HibTITER,” Jablonowski told The Defender. “In VAERS’ first six months of existence, 30% of mortalities reported in children 6 months old or younger were HibTITER recipients.”

HibTITER dominated the Hib vaccine market between 1991 and 1994 when it began to share the market with other FDA-approved vaccines.

Wyeth allowed the license for the thimerosal-containing HibTITER to expire in 2002, following the CDC’s Simpsonwood retreat. At the meeting of public health officials, vaccine manufacturers and professional medical associations reviewed data from the Vaccine Safety Datalink and privately raised concerns about thimerosal in vaccines.

The license expired just after the Institute of Medicine’s Immunization Safety Review Committee published its 2001 safety review of thimerosal-containing vaccines and their link to neurodevelopmental disorders.

In that report, the Institute of Medicine found insufficient data to confirm or deny the link, yet the CDC recommended removing thimerosal from vaccines “as soon as possible.”

However, even when Wyeth began selling a reformulated non-thimerosal version of HibTITER in 2003, adverse events continued to occur at high rates.

“In the subsequent years, HibTITER accounted for a disproportionately larger number of emergency room visits, serious reports and reports of death,” Jablonowski said. “The FDA and CDC took no known action, and instead allowed the manufacturer, Wyeth, to choose to end production.”

The researchers estimated that approximately 35 million Americans received the HibTITER vaccine during its time on the market.

In 2011, vaccine maker Nuron Biotech Inc. acquired the HibTITER rights from Wyeth/Pfizer and announced it was preparing to rerelease the vaccine in the U.S. and some Asian markets.

However, the shot was never reintroduced to the U.S. market and the company no longer exists.

‘We were stunned at what the data revealed’

The investigators compared the frequencies of new diseases identified within 30 days of vaccination among 152,269 infants who received the thimerosal-free HibTITER to 125,215 infants who received any other Hib vaccine.

They employed the Fisher’s Exact Test statistical model to compare disease frequency in each cohort and used Bonferroni correction, a powerful statistical tool, to eliminate random results. They also set a high bar for statistical significance.

They identified 19 adverse outcomes with the “most prolific, significant signals” for infectious diseases, such as pulmonary tuberculosis, where 99.03% of diagnoses were among HibTITER recipients.

Other respiratory illnesses occurring within 30 days of HibTITER vaccination included asthma, acute upper respiratory infections, influenza and acute bronchiolitis. Additional diseases included laryngopharyngitis, common cold, colitis, enteritis and gastroenteritis.

Of the 19 adverse effects they identified, the most recent package insert for HibTITER named only two: fever and rash. Infectious diseases accounted for nine of the 19 adverse effects.

Jablonowski explained that the HibTITER doesn’t directly cause infections but can create conditions that facilitate them. The presence of so many infections “implicates significant and rapid immunological defense impairment,” he said.

Jablonowski added:

“While we had heard anecdotally of many adverse reactions to the HibTITER vaccine, we were stunned at what the data revealed.

“This vaccine should have been studied much more intensively before being allowed on the market. In fact, it shouldn’t have ever been allowed to be injected into infants in the absence of rigorous studies to support its safety.”

He said analyzing the adverse outcomes was “simple — high-school level math and basic database/programming skills kind-of-simple. There are literally millions of people in this country who could have performed the data science portion of this study, and none of them apparently work for the FDA or CDC.”

By Brenda Baletti, Ph.D.